Document Detail

Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.
MedLine Citation:
PMID:  21494579     Owner:  NLM     Status:  MEDLINE    
Reproducible cytogenetic analysis in CLL has been limited by the inability to obtain reliable metaphase cells for analysis. CpG oligonucleotide and cytokine stimulation have been shown to improve metaphase analysis of CLL cytogenetic abnormalities, but is limited by variability in the cytokine receptor levels, stability and biological activity of the cytokine in culture conditions and high costs associated with these reagents. We report here use of a novel, stable CpG, GNKG168 along with pokeweed mitogen (PWM) and phorbol 12-myristate 13-acetate (PMA) for conventional cytogenetic assessment in CLL. We demonstrate that the combined use of GNKG168+PWM/PMA increased the sensitivity of detection of chromosomal abnormalities compared to PWM/PMA (n=207, odds ratio=2.2, p=0.0002) and GNKG168 (n=219, odds ratio=1.5, p=0.0452). Further, a significant increase in sensitivity to detect complexity ≥3 with GNKG168+PWM/PMA compared to GNKG168 alone (odds ratio 8.0, p=0.0022) or PWM/PMA alone (odds ratio 9.6, p=0.0007) was observed. The trend toward detection of higher complexity was significantly greater with GNKG168+PWM/PMA compared to GNKG168 alone (p=0.0412). The increased sensitivity was mainly attributed to the addition of PWM/PMA with GNKG168 because GNKG168 alone showed no difference in sensitivity for detection of complex abnormalities (p=0.17). Comparison of fluorescence in situ hybridization (FISH) results with karyotypic results showed a high degree of consistency, although some complex karyotypes were present in cases with no adverse FISH abnormality. These studies provide evidence for potential use of GNKG168 in combination with PWM and PMA in karyotypic analysis of CLL patient samples to better identify chromosomal abnormalities for risk stratification.
Natarajan Muthusamy; Heather Breidenbach; Leslie Andritsos; Joseph Flynn; Jeffrey Jones; Asha Ramanunni; Xiaokui Mo; David Jarjoura; John C Byrd; Nyla A Heerema
Related Documents :
21416559 - Atypical developmental trajectory of functionally significant cortical areas in childre...
155399 - Abnormal skin fibroblast cytogenetics in four dysmorphic patients with normal lymphocyt...
19850629 - Noninvasive prenatal detection of trisomy 21 by an epigenetic-genetic chromosome-dosage...
3325969 - Direct chromosomal preparation for studying hydatidiform moles.
21155139 - Ftsk--a bacterial cell division checkpoint?
21518249 - Identification of a stable quantitative trait locus for percentage grains with white ch...
7192199 - Regional localization of the genes coding for human aco2, arsa, and naga on chromosome 22.
19238339 - Genome-wide search for genes that modulate inflammatory arthritis caused by ali18 mutat...
1267059 - The role of neurosis in phylogenetic adaptation, with particular reference to early man.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer genetics     Volume:  204     ISSN:  2210-7762     ISO Abbreviation:  Cancer Genet     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-04-20     Completed Date:  2011-06-13     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  101539150     Medline TA:  Cancer Genet     Country:  United States    
Other Details:
Languages:  eng     Pagination:  77-83     Citation Subset:  IM    
Division of Hematology, The OSU Comprehensive Cancer Center, The Ohio State University, Columbus, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Chromosome Aberrations*
Karyotyping / methods*
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*,  genetics*
Middle Aged
Oligodeoxyribonucleotides / diagnostic use
Pokeweed Mitogens / diagnostic use
Sensitivity and Specificity
Tetradecanoylphorbol Acetate / diagnostic use
Grant Support
1K12 CA133250/CA/NCI NIH HHS; P01 CA101956/CA/NCI NIH HHS; P01 CA95426/CA/NCI NIH HHS; P50 CA140158/CA/NCI NIH HHS; P50 CA140158-03/CA/NCI NIH HHS; P50-CA140158/CA/NCI NIH HHS
Reg. No./Substance:
0/GNKG168; 0/Oligodeoxyribonucleotides; 0/Pokeweed Mitogens; 16561-29-8/Tetradecanoylphorbol Acetate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fast and slow effects of medial olivocochlear efferent activity in humans.
Next Document:  Opposing roles for CD34 in B16 melanoma tumor growth alter early stage vasculature and late stage im...